In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 1, 2014, Pages

  Yeap, Bu B ^a,b   Alfonso, Helman ^c   Paul Chubb, S A ^a,d   Handelsman, David J ^e   Hankey, Graeme J ^a   Almeida, Osvaldo P ^c,f   Golledge, Jonathan ^g   Norman, Paul E ^f   Flicker, Leon ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g JAMES COOK UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; BIOLOGICAL MARKER; ESTRADIOL; TESTOSTERONE;

AGED; ANDROGEN BLOOD LEVEL; ARTICLE; AUSTRALIA; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; CORRELATION ANALYSIS; ESTRADIOL BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TANDEM MASS SPECTROMETRY; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DIHYDROTESTOSTERONE; ESTRADIOL; HUMANS; MALE; MYOCARDIAL ISCHEMIA; PROGNOSIS; REFERENCE STANDARDS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; WESTERN AUSTRALIA;

EID: 84892141468     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3272     Document Type: Article

References (42)

1. Handelsman DJ. Androgen physiology, pharmacology and abuse. In: De Groot LJ, Jameson JL, eds. Endocrinology. 6th ed. Philadelphia, PA: Elsevier Saunders; 2010:2469-2498.
2. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-731.
3. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87:589-598.
4. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005; 26:833-876.
5. Yeap BB, Almeida OP, Hyde Z, et al. In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health In Men Study. Eur J Endocrinol. 2007;156:585-594.
6. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011;97:870-875.
7. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:3007-3019.
8. Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009;94:2353-2359.
9. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050-2058.
10. Wu FC. Caveat emptor: does testosterone treatment reduce mortality in men? J Clin Endocrinol Metab. 2012;97:1884-1886.
11. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
12. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.
13. Cunningham GR, Toma SM. Clinical review: Why is androgen replacement in males controversial? J Clin Endocrinol Metab. 2011; 96:38-52.
14. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
15. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63:280-293.
16. Cauley JA, Ewing SK, Taylor BC, et al. Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density-the Osteoporotic Fractures in Men Study. J Clin Endocrinol Metab. 2010;95:4314-4323.
17. Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab. 2004;89:5898-5907.
18. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med. 2007;167:1252-1260.
19. Tivesten A, Hulthe J, Wallenfeldt K, Wikstrand J, Ohlsson C, Fagerberg B. Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle-aged men. J Clin Endocrinol Metab. 2006;91:4433-4437.
20. Abbott RD, Launer LJ, Rodriguez BL, et al. Serum estradiol and risk of stroke in elderly men. Neurology. 2007;68:563-568.
21. Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab. 2009;94:2482-2488.
22. Hyde Z, Norman PE, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: The Health in Men Study. J Clin Endocrinol Metab. 2012;97:179-189.
23. Shackleton C. Clinical steroid mass spectrometry: a 45-year history culminating in HPLC-MS/MS becoming an essential tool for patient diagnosis. J Steroid Biochem Mol Biol. 2010;121:481-490.
24. Norman PE, Flicker L, Almeida OP, Hankey GJ, Hyde Z, Jamrozik K. Cohort profile: the Health In Men Study (HIMS). Int J Epidemiol. 2009;38:48-52.
25. The Australian Diabetes, Obesity and Lifestyle Study. Diabesity and Associated Disorders in Australia 2000. Melbourne, Australia: International Diabetes Institute; 2000:7-12.
26. Holman CD, Bass AJ, Rosman DL, et al. A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. Aust Health Rev. 2008;32:766-777.
27. Harwood DT, Handelsman DJ. Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. Clin Chim Acta. 2009;409:78-84.
28. Yeap BB, Alfonso H, Chubb SA, et al. Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. J Clin Endocrinol Metab. 2012;97:4030-4039.
29. Ly LP, Sartorius G, Hull L, et al. Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf). 2010;73:382-388.
30. Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research. 4th ed. Oxford, UK: Blackwell Science; 2002:83-146.
31. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007; 116:2694-2701.
32. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008; 93:68-75.
33. Menke A, Guallar E, Rohrmann S, et al. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol. 2010; 171:583-592.
34. Tivesten A, Mellström D, Jutberger H, et al. Lowserum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol. 2007;50:1070-1076.
35. Yeap BB, Alfonso H, Chubb SAP, et al. Lower plasma testosterone or dihydrotestosterone, but not estradiol, are associated with symptoms of intermittent claudication in older men. Clin Endocrinol (Oxf). 2013;79:725-732.
36. Vandenplas G, De Bacquer D, Calders P, et al. Endogenous oestradiol and cardiovascular disease in healthy men: a systematic review and meta-analysis of prospective studies. Heart. 2012;98:1478-1482.
37. Vermeulen A, Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab. 1992;74:939-942.
38. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53:58-68.
39. Hyde Z, Flicker L, Almeida OP, et al. Low free testosterone predicts frailty in older men: the Health in Men Study. J Clin Endocrinol Metab. 2010;95:3165-3172.
40. Sieveking DP, Lim P, Chow RW, et al. A sex-specific role for androgens in angiogenesis. J Exp Med. 2010;207:345-352.
41. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebocontrolled study. Circulation. 2000;102:1906-1911.
42. Lakshman KM, Kaplan B, Travison TG, et al. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab. 2010;95:3955-3964.